Hong Wan is the founder of Tallac Therapeutics. Tallac Therapeutics has raised $62M in total funding. Latest round: Series A.
Hong Wan is the President, CEO, and Co-founder of Tallac Therapeutics, a privately held biopharmaceutical company focused on developing novel immunotherapies for cancer. The company utilizes its Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform. Tallac Therapeutics launched with a $62 million Series A financing round in December 2020. Previously, Dr. Wan served as CSO of ALX Oncology.
Full founder directory · Investor directory · Company funding database · Fundraising library